© 2008 European Society of Cardiology
Can B-type natriuretic peptides replace heart failure risk models?
University of Washington, Division of Cardiology Box 356422, 1959 NE Pacific Street, Seattle, WA 98195, United States E-mail address: levywc@u.washington.edu. Tel.: +1 206 221 4507; fax: +1 206 221 6835.
Received December 10, 2007;
| The first 10% of the full text of this article appears below. |
The article by Dr. Pfister and colleagues published in this issue of the European Journal of Heart Failure, compares the prognostic value of the biomarker NT-proBNP and glomerular filtration rate (GFR) with the multivariate CHARM CV morbidity and mortality model and the Seattle Heart Failure Model (SHFM) [1]. The authors found that NT-proBNP was a very powerful risk marker with a hazard ratio of 2.1 for 1 SD increase in log NT-proBNP with a 1-year ROC of 0.80.
However, the group of heart failure patients evaluated was unusual; 65% were evaluated at hospital discharge and 68% of these were NYHA 1 or 2. In addition, the